Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
Figure 1
Flowchart of the study. All subjects treated with FCM or DEX were included in the safety population. mITT: all subjects in the safety population with 2 baseline hemoglobin values (with <1 g/dL difference between the 2 values) and at least 1 postbaseline hemoglobin value on or before Day 49 or intervention date, whichever came first.
